Compass Pathways and Atai Life Sciences could do something special over the next five years as psychedelic medicine gains federal support. Psychedelic stocks rallied after Trump ordered faster PTSD research, with Compass up 25% pre-market. x.com 

Definium Therapeutics edges out Compass Pathways on peak potential, though both have good management and unique psychedelic drugs. Compass's lead indication, treatment-resistant depression, and Definium's, generalized anxiety disorder, are each about $1.5 billion opportunities, and both target PTSD. Definium also has strong MDD data, adding a $2-3 billion indication. Its LSD session lasts only about six hours, not the 12 hours critics cite. x.com  x.com 

TransMedics, Hims & Hers, Harrow, PROCEPT BioRobotics, ClearPoint Neuro, Alphatec and Compass Pathways can double in 2–3 years and triple in 3–5 because these small- and mid-cap healthcare names trade at only 2–3x next-12-month revenue. Software and cloud stocks people are chasing at 20–30x make such returns hard. Alphatec looks attractive after its earnings selloff, while Compass is very speculative and should not be chased. x.com 

Helus Pharma offers the most outsized upside in psychedelics: political tailwinds may push some therapies through on weak evidence, and it trades at a tenth of Compass Pathways' and ATAI's valuations. Approval costs politicians little, with Leucovorin and peptides as precedents and Joe Rogan's sway possibly feeding midterms. Helus posted the best efficacy, on a small sample. It just raised cash and rarely raises opportunistically, while ATAI and Compass need cash, so downside looks lowest. x.com  … Show more

Definium Therapeutics has turned from a high-risk bet into a much safer biotech investment after its single-dose DT120 cleared phase 3 in three of four major trials, all headed to the FDA together. Success in the fourth looks priced in, so full FDA approval is the next catalyst, plus possible Trump administration psychedelics moves. Analyst targets of $70-90 could be reached with commercialization in a couple of years, though more multibaggers are unlikely. Support should hold near $35. x.com 

Axsome Therapeutics is a one-hit wonder rather than a broad pipeline of blockbusters. It has one good drug in Auvelity, and the rest of its drugs are very weak. Excitement around the upcoming PDUFA date is a chance to sell at a premium price. x.com 

Taysha Gene Therapies is a high-conviction binary bet: cash cushions the downside, and FDA approval of TSHA-102 for Rett syndrome could be a 5-10x event. No disease-modifying Rett therapy exists today, and TSHA-102 has a clean safety record in 12 patients, while rival Neurogene's NGN-401 lost its high-dose arm after a patient death. Comparables suggest $2-4 million a dose against about $10,000 in cost. Cash of $319.8 million lasts into 2028, but another raise is likely; failure means near zero. … Show more

Big pharma's push into psychedelics, with Eli Lilly buying Atai Life Sciences after AbbVie's deal, is positive for Helus Pharma, the only other company identified with new-chemical-entity patent protection in the field. Helus looks about two years ahead of Atai, with stronger treatment-resistant depression data, at a fraction of its valuation. Its drawback is two dosing sessions of 3-4 hours each versus Atai's single 90-minute visit, so it stays a higher-risk holding. x.com